Pfizer Inc. and BioNTech SE have signed an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the EU.
A resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells.
Cellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellink_management.jpeg10601102Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-15 08:26:562021-02-15 08:26:56Cellink AB acquires Ginolis Oy for €70m
MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company.
https://european-biotechnology.com/wp-content/uploads/2024/04/Interna.jpg394768Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-02-09 14:07:332021-02-09 14:07:33InteRNA Technologies secures €18.5m in Series B financing
Management changes at Abliva
AppointmentsLund-based Abliva AB named Dr Ellen Donnelly as its new CEO. At the beginning of February she succeeded Dr Erik Kinnmann, who had been CEO since 2018.
MaxiVAX and Minaris Regenerative Medicine ink contract
Latest NewsSwiss cancer vaccine specialist MaxiVAX SA has hired Minaris Regenerative Medicine GmbH to produce its cell therapy MVX-ONCO-2.
EU orders additional COVID-19 vaccine doses
Latest NewsPfizer Inc. and BioNTech SE have signed an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the EU.
Novel strategy targets chronic liver diseases
Latest NewsA resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells.
Swedish AlzeCure appoints CMO
AppointmentsMärta Segerdahl will take over the position as Chief Medical Officer of Swedish AlzeCure Pharma AB on April.
Cellectis and Cytovia in US$760m licence deal
Latest NewsCell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
Higher omega-3 level apparently protects from dying from COVID-19
Sponsored PublicationsCellink AB acquires Ginolis Oy for €70m
Latest NewsCellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.
Rentschler Biopharma launches gene therapy subsidiary
Latest NewsCDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.
InteRNA Technologies secures €18.5m in Series B financing
Latest NewsMicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling €18.5m led by AurorA Science, an Italian biotech investment company.